<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30895/1991-2919-2023-543</article-id><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МИКРОБИОЛОГИЧЕСКИЙ АНАЛИЗ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MICROBIOLOGICAL TESTING</subject></subj-group></article-categories><title-group><article-title>Микробиологический анализ качества лекарственных препаратов в формах аэрозолей и спреев</article-title><trans-title-group xml:lang="en"><trans-title>Microbiological examination of aerosols and sprays</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4825-8356</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гунар</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gunar</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гунар Ольга Викторовна, д-р фарм. наук</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Olga V. Gunar, Dr. Sci. (Pharm.)</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">gunar@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1773-7423</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сахно</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sakhno</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сахно Надежда Геннадьевна, канд. фарм. наук</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Nadezhda G. Sakhno, Cand. Sci. (Pharm.)</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">sakhno@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><fpage>464</fpage><lpage>473</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гунар О.В., Сахно Н.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Гунар О.В., Сахно Н.Г.</copyright-holder><copyright-holder xml:lang="en">Gunar O.V., Sakhno N.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/543">https://www.vedomostincesmp.ru/jour/article/view/543</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Лекарственные препараты в форме аэрозолей и спреев все более активно применяются в медицинской практике, в связи с чем актуальным оказывается вопрос контроля их качества, в частности по микробиологическим показателям. В действующей нормативной документации рекомендации по проведению микробиологических испытаний дозированных аэрозольных препаратов представлены в недостаточном объеме. Форма первичной упаковки затрудняет извлечение необходимого для анализа количества образца. Методики испытания, описанные в зарубежной документации, требуют апробации и стандартизации. Лекарственные препараты (ЛП) в форме спреев лишены недостатков аэрозольных форм, но более подвержены риску микробной контаминации.</p></sec><sec><title>Цель</title><p>Цель. Описание методики пробоподготовки образцов, анализ результатов микробиологического испытания лекарственных препаратов в формах аэрозолей и спреев, определение спектра микроорганизмов-контаминантов данных лекарственных форм.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен ретроспективный анализ данных микробиологических испытаний образцов ЛП, выполненных в 2020–2022 гг. в лаборатории микробиологии ИЦЭКЛС ФГБУ «НЦЭСМП» Минздрава России. Исследованы образцы 181 серии ЛП в форме спреев, аэрозолей и других лекарственных форм для ингаляций по показателям «Микробиологическая чистота» и «Стерильность». Испытания проведены в соответствии с нормативной документацией производителей по утвержденным методикам согласно Государственной фармакопее Российской Федерации и Фармакопее Евразийского экономического союза текущего издания.</p></sec><sec><title>Результаты</title><p>Результаты. 2,8% серий проанализированных ЛП содержали микроорганизмы в количестве, превышающем допустимые значения. Установлен видовой состав контаминантов ЛП, не соответствующих нормативным требованиям по изученным показателям. Из большинства спреев, содержащих бензалкония хлорид в качестве консерванта, были выделены бактерии Burkholderia cepacia complex.</p></sec><sec><title>Выводы</title><p>Выводы. Представляется актуальным проведение исследований по усовершенствованию имеющихся методик микробиологического анализа аэрозолей и спреев с учетом данных о потенциально нежелательных контаминантах.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Scientific relevance</title><p>Scientific relevance. Medicinal products formulated as aerosols and sprays are increasingly used in clinical practice, which makes the control of their quality, including microbiological testing, a highly topical issue. The current regulatory standards for microbiological testing of medicines provide little information on the quality control of metereddose aerosols. Proper microbiological sampling of these medicinal products can be difficult because of their primary packaging. The specialised analytical procedures set forth in international standards require verification and standardisation before use. Medicinal products in the form of sprays, despite being free from the disadvantages of aerosols, are more susceptible to the risk of microbial contamination.</p></sec><sec><title>Aim</title><p>Aim. The study aimed to describe specific aspects of sampling, to analyse the results of microbiological testing of aerosols and sprays, and to study the spectrum of microbial contaminants in these dosage forms.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The authors retrospectively analysed the microbiological quality and sterility data for 181 batches of sprays, aerosols, and other inhalation dosage forms. The data were obtained at the Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of Russia in 2020–2022. The Microbiology Laboratory tested the dosage forms according to the specifications provided by the manufacturers. The analysts used well-established testing procedures outlined in the current pharmacopoeias of the Russian Federation and the Eurasian Economic Union.</p></sec><sec><title>Results</title><p>Results. The microbial counts exceeded the acceptable limits in 2.8% of the batches tested. The authors identified the microbial species that contaminated the medicinal products found to be non-compliant with regulatory requirements. Most of the non-compliant sprays that contained benzalkonium chloride as an antibacterial preservative were contaminated with Burkholderia cepacia complex species.</p></sec><sec><title>Conclusions</title><p>Conclusions. The authors consider it relevant to conduct research aiming at using the findings on potential contaminants to improve microbiological testing procedures for aerosols and sprays.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аэрозоли</kwd><kwd>спреи</kwd><kwd>качество</kwd><kwd>микробиологическая чистота</kwd><kwd>Burkholderia cepacia complex</kwd></kwd-group><kwd-group xml:lang="en"><kwd>aerosols</kwd><kwd>sprays</kwd><kwd>quality</kwd><kwd>microbiological quality</kwd><kwd>Burkholderia cepacia complex</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00052-23-00 на проведение прикладных научных исследований (номер государственного учета НИР 121021800098-4).</funding-statement><funding-statement xml:lang="en">The study reported in this publication was carried out as part of publicly funded research project No. 056-00052-23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&amp;D public accounting No. 121021800098-4).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20–41. https://doi.org/10.1089/jamp.2016.1297</mixed-citation><mixed-citation xml:lang="en">Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20–41. https://doi.org/10.1089/jamp.2016.1297</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Победин ОА, Трухачева ЛА, Нечаева ЕБ. Анализ критериев оценки качества дозированных аэрозольных ингаляторов. Ведомости Научного центра экспертизы средств медицинского применения. 2014;(2):20–5. EDN: SIOVDF</mixed-citation><mixed-citation xml:lang="en">Pobedin OA, Trukhacheva LA, Nechayeva EB. Quality assessment criteria for inhalation dosage forms. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2014;(2):20–5 (In Russ.). EDN: SIOVDF</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Гобызов ОА, Рябов МН, Янкова ВГ, Грибанова СВ, Удянская ИЛ, Григорьева ВЮ, Сазонова ОП. Сравнительный анализ показателей распыления препаратов Каметон разных производителей. Вестник оториноларингологии. 2019;84(1):72–7. EDN: MBGGIK</mixed-citation><mixed-citation xml:lang="en">Gobyzov OA, Ryabov MN, Yankova VG, Gribanova SV, Udyanskaya IL, Grigorieva VYu, Sazonova OP. Comparative analysis of Kameton spraying parameters of different manufacturers. Bulletin of Otorhinolaryngology. 2019;84(1):72–7 (In Russ.). EDN: MBGGIK</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Сушинская ОА, Голяк НС. Анализ ассортимента лекарственных средств в виде спреев в Республике Беларусь. Инновации в медицине и фармации — 2016: материалы дистанцион. науч.-практ. конф. студентов и молодых ученых. Минск: БГМУ; 2016. C. 814–8.</mixed-citation><mixed-citation xml:lang="en">Sushinskaya OA, Golyak NS. Analysis of the range of medicines in the form of sprays in the Republic of Belarus. Innovations in medicine and pharmacy — 2016: materials of remote scientific-practical conference of students and young scientists. Minsk: BSMU; 2016. P. 814–8 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Абдыкадырова МК, Жетерова СК. Разработка современной лекарственной формы — спрея, противогрибкового действия. Вестник КазНМУ. 2015;(1):377–9. EDN: ZVICFX</mixed-citation><mixed-citation xml:lang="en">Abdykadyrova MK, Zheterova SK. The development of modern pharmaceutical form—spray, antifungal action. Bulletin of KazNMU. 2015;(1):377–9 (In Russ.). EDN: ZVICFX</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чекман ИС, Сыровая АО, Андреева СВ, Макаров ВА. Аэрозоли — дисперсные системы. Киев-Харьков: Цифрова друкарня № 1; 2013.</mixed-citation><mixed-citation xml:lang="en">Chekman IS, Syrovaja AO, Andreeva SV, Makarov VA. Aerosols—dispersed systems. Kiev-Kharkiv: Digital Printing House No. 1; 2013 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кинев МЮ, Петров АЮ. Сравнительный анализ отечественного и зарубежного фармацевтических рынков спреев для носа с целью поиска перспектив дальнейшей их разработки. Разработка и регистрация лекарственных средств. 2018;(1):216–24. EDN: YRTLFK</mixed-citation><mixed-citation xml:lang="en">Kinev MYu, Petrov AYu. Сomparative analysis of the domestic and foreign pharmaceutical markets for the nose with the purpose of searching for future development prospects. Drug Development and Registration. 2018;(1):216–24 (In Russ.). EDN: YRTLFK</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares M, Kozak M, Balola A, Sá-Correia I. Burkholderia cepacia complex bacteria: a feared contamination risk in water-based pharmaceutical products. Clin Microbiol Rev. 2020;33(3):e00139-19. https://doi.org/10.1128/CMR.00139-19</mixed-citation><mixed-citation xml:lang="en">Tavares M, Kozak M, Balola A, Sá-Correia I. Burkholderia cepacia complex bacteria: a feared contamination risk in water-based pharmaceutical products. Clin Microbiol Rev. 2020;33(3):e00139-19. https://doi.org/10.1128/CMR.00139-19</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Torbeck L, Raccasi D, Guilfoyle DE, Friedman RL, Hussong D. Burkholderia cepacia: this decision is overdue. PDA J Pharm Sci Technol. 2011;65(5):535–43. https://doi.org/10.5731/pdajpst.2011.00793</mixed-citation><mixed-citation xml:lang="en">Torbeck L, Raccasi D, Guilfoyle DE, Friedman RL, Hussong D. Burkholderia cepacia: this decision is overdue. PDA J Pharm Sci Technol. 2011;65(5):535–43. https://doi.org/10.5731/pdajpst.2011.00793</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ali M. Burkholderia cepacia in pharmaceutical industries. Int J Vaccines Vaccin. 2016;3(2):11–2. https://doi.org/10.15406/ijvv.2016.03.00064</mixed-citation><mixed-citation xml:lang="en">Ali M. Burkholderia cepacia in pharmaceutical industries. Int J Vaccines Vaccin. 2016;3(2):11–2. https://doi.org/10.15406/ijvv.2016.03.00064</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Carson L, Favero MS, Bond WW, Peterson NJ. Morphological, biochemical, and growth characteristics of Pseudomonas cepacia from distilled water. Appl Microbiol. 1973;25(3):476–83. https://doi.org/10.1128/am.25.3.476-483.1973</mixed-citation><mixed-citation xml:lang="en">Carson L, Favero MS, Bond WW, Peterson NJ. Morphological, biochemical, and growth characteristics of Pseudomonas cepacia from distilled water. Appl Microbiol. 1973;25(3):476–83. https://doi.org/10.1128/am.25.3.476-483.1973</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Seelman SL, Bazaco MC, Wellman A, Hardy C, Fatica MK, Huang MJ, et al. Burkholderia cepacia complex outbreak linked to a no-rinse cleansing foam product, United States—2017–2018. Epidemiology and Infection. 2022;150:e154. https://doi.org/10.1017/S0950268822000668</mixed-citation><mixed-citation xml:lang="en">Seelman SL, Bazaco MC, Wellman A, Hardy C, Fatica MK, Huang MJ, et al. Burkholderia cepacia complex outbreak linked to a no-rinse cleansing foam product, United States—2017–2018. Epidemiology and Infection. 2022;150:e154. https://doi.org/10.1017/S0950268822000668</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Колосова ЛВ, Рощина МВ, Гунар ОВ. Контаминация лекарственных препаратов бактериями Burkholderia cepacia. Фармация. 2017;66(7):8–10. EDN: ZQNWQH</mixed-citation><mixed-citation xml:lang="en">Kolosova LV, Roshchina MV, Gunar OV. Drug contamination with the bacteria Burkholderia cepacia. Pharmacy. 2017;66(7):8–10 (In Russ.). EDN: ZQNWQH</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lord R, Jones AM, Horsley A. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. 2020;4(4):CD009529. https://doi.org/10.1002/14651858.CD009529.pub4</mixed-citation><mixed-citation xml:lang="en">Lord R, Jones AM, Horsley A. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. 2020;4(4):CD009529. https://doi.org/10.1002/14651858.CD009529.pub4</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Незнамова АВ, Лопастейская ЯА, Молчанова ЕВ, Агеева НП, Викторов ДВ. Особенности идентификации микроорганизмов комплекса Burkholderia cepacia и рода Pseudomonas с помощью биохимического автоматического анализатора VITEK 2. Вестник Волгоградского государственного медицинского университета. 2016;(3):109–12. EDN: WMIEBH</mixed-citation><mixed-citation xml:lang="en">Neznamova AV, Lopasteiskaya YaA, Molchanova EV , Ageeva NP , Viktorov DV. Identification of Burkholderia cepacia complex and Pseudomonas spp. using Vitek 2, an automated biochemical analyzer. Journal of VolgSMU, 2016;(3):109–12. EDN: WMIEBH</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kampf G. Adaptive microbial response to low-level benzalkonium chloride exposure. J Hosp Infect. 2018;100(3):e1–22. https://doi.org/10.1016/j.jhin.2018.05.019</mixed-citation><mixed-citation xml:lang="en">Kampf G. Adaptive microbial response to low-level benzalkonium chloride exposure. J Hosp Infect. 2018;100(3):e1–22. https://doi.org/10.1016/j.jhin.2018.05.019</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004;130(1):131–41. https://doi.org/10.1016/j.otohns.2003.07.005</mixed-citation><mixed-citation xml:lang="en">Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004;130(1):131–41. https://doi.org/10.1016/j.otohns.2003.07.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Лучинин ДН, Молчанова ЕВ, Захарова ИБ, Викторов ДВ. Анализ резистентности у Burkholderia pseudomallei к бензалкония хлориду и антибиотикам. Проблемы особо опасных инфекций. 2022;(3):115–19. https://doi.org/10.21055/0370-1069-2022-3-115-119</mixed-citation><mixed-citation xml:lang="en">Luchinin DN, Molchanova EV, Zakharova IB, Viktorov DV. Assessment of resistance in Burkholderia pseudomallei to benzalkonium chloride and antibiotics. Problems of Particularly Dangerous Infections. 2022;(3):115–9 (In Russ.). https://doi.org/10.21055/0370-1069-2022-3-115-119</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ahn Y, Kim JM, Kweon O, Kim SJ, Jones RC, Woodling K, et al. Intrinsic resistance of Burkholderia cepacia complex to benzalkonium chloride. mBio. 2016;7(6):e01716-16. https://doi.org/10.1128/mBio.01716-16</mixed-citation><mixed-citation xml:lang="en">Ahn Y, Kim JM, Kweon O, Kim SJ, Jones RC, Woodling K, et al. Intrinsic resistance of Burkholderia cepacia complex to benzalkonium chloride. mBio. 2016;7(6):e01716-16. https://doi.org/10.1128/mBio.01716-16</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares M, Kozak M, Balola A, Coutinho CP, Godinho CP, Hassan AA, et al. Adaptation and survival of Burkholderia cepacia and B. contaminans during long-term incubation in saline solutions containing benzalkonium chloride. Front. Bioeng. Biotechnol. 2020;(8):630. https://doi.org/10.3389/fbioe.2020.00630</mixed-citation><mixed-citation xml:lang="en">Tavares M, Kozak M, Balola A, Coutinho CP, Godinho CP, Hassan AA, et al. Adaptation and survival of Burkholderia cepacia and B. contaminans during long-term incubation in saline solutions containing benzalkonium chloride. Front. Bioeng. Biotechnol. 2020;(8):630. https://doi.org/10.3389/fbioe.2020.00630</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Johns BE, Purdy KJ, Tucker NP, Maddocks SE. Phenotypic and genotypic characteristics of small colony variants and their role in chronic infection. Microbiol Insights. 2015;8:15–23. https://doi.org/10.4137/MBI.S25800</mixed-citation><mixed-citation xml:lang="en">Johns BE, Purdy KJ, Tucker NP, Maddocks SE. Phenotypic and genotypic characteristics of small colony variants and their role in chronic infection. Microbiol Insights. 2015;8:15–23. https://doi.org/10.4137/MBI.S25800</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jimenez L. Microbial contamination control in the pharmaceutical industry. New York: Marcel Dekker; 2004.</mixed-citation><mixed-citation xml:lang="en">Jimenez L. Microbial contamination control in the pharmaceutical industry. New York: Marcel Dekker; 2004.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Devanga Ragupathi NK, Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob. 2019;18(1):7. https://doi.org/10.1186/s12941-019-0306-0</mixed-citation><mixed-citation xml:lang="en">Devanga Ragupathi NK, Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob. 2019;18(1):7. https://doi.org/10.1186/s12941-019-0306-0</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
